The drug can now be used to treat locally advanced head and neck cancer prior to chemoradiotherapy and surgery, Sanofi-Aventis said in a statement.
Advanced clinical trials showed that using Taxotere in combination with standard induction chemotherapy resulted in a more than three year improvement in patient survival rate, the company said.
More than 640,000 people worldwide are diagnosed with head and neck cancer each year, and more than 350,000 die from the disease annually, the company said.
Sanofi-Aventis' shares were down 0.1 percent at EUR59.33 (US$84.12) in Paris.
The Kremlin believes that new possible sanctions against Russia may lead to disastrous consequences, as Washington's actions will come contrary to the generally accepted rules of international trade